BeyondSpring Inc. (BYSI) shares surged 12.61% in after-hours on Friday, November 26, 2021, and closed the weekly trading at $16.16. Even in the regular trading session of Friday, BYSI’s stock gained 8.06%. BYSI shares have risen 31.77% over the last 12 months, and they have moved up 7.73% in the past week. Over the past three months, the stock has lost 50.17%, while over the past six months, it has gained 38.38%.
Let’s see is there any recent news behind its good performance on Friday?
BYSI participation in the upcoming event
BeyondSpring (BYSI) management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, which is to be held on November 30-December 2, 2021.
BYSI participation in the recent event
BeyondSpring (BYSI) recently participated at Jefferies London Healthcare Conference which was held on November 18-19, 2021. The company had one-on-one investor meetings during the event.
BYSI new appointment
On November 10, 2021, BeyondSpring Pharmaceuticals (BYSI), appointed Mark Santos, RPh, to its Board of Directors. Mr. Santos has over 30 years of executive experience across the healthcare and pharmaceutical industries, currently serving as the Senior Vice President of Pharma Strategy & Contracting at OneOncology. He was President of ION Solutions, the leading GPO in the U.S., from 2011 to 2018.
BYSI update about plinabulin
On October 21, 2021, BeyondSpring (BYSI) announced that the first patient has been treated in an investigator-initiated, open-label Phase 2 study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3rd line recurrent small-cell lung cancer (SCLC) who failed checkpoint inhibitors and platinum-based chemotherapy. This Phase 2 study, to be conducted through the Big Ten Cancer Research Consortium in 7 U.S. clinical centres, comes after the successful completion of Phase 1 dose-escalation study portion of this Phase 1/2 study.
Plinabulin ability to enhance the anti-cancer effects and reduce the Grade 3/4 IR-AEs of PD-1 and CTLA-4 inhibitors makes it an ideal addition to these checkpoint inhibitors for establishing the concept of a ‘chemo free therapeutic strategy for cancer patients.
Well, as of this writing, there is no recent news which could be linked with its good performance on Friday. We hope that it will continue its momentum on Monday as well.